Abstract
Transdermal drug delivery systems (TDDS), which are self-administrable and non-invasive, can improve bioavailability and patient compliance by bypassing first-pass metabolism. Vesicular-based TDDS have attracted a lot of attention in recent years because they're designed for controlled, efficient, and targeted drug delivery. One of these delivery technologies, transferosomal-based formulations, has grown in popularity due to its ability to achieve all of the desired criteria and quality qualities. Transferosomes combine the characteristics of liposomes and niosomes because they contain both liposomes (phospholipids and cholesterols) and niosomes as components (nonionic surfactants; edge activators). as a result, they are referred to as the first generation of elastic liposomes. However transdermal drug delivery is difficult due to the presence of the skin's protective barrier, transferosomal drug delivery overcomes all obstacles due to its unique characteristics, such as its ultradeformable vesicular nature. The benefits, limitations, modes of penetration, formulations, production and assessment methodologies, and pharmaceutical uses of transferosomal drug delivery systems are discussed in this paper.
 Conclusion: Transferosomes have several importance over other vesicular systems, including greater deformability, greater penetration power across skin, the ability to deliver systemic drugs, and higher stability.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
